Advancing Rare Disease Development Strategies

This report presents strategies for advancing the development of novel therapies for rare diseases. It outlines the importance of patient-centric approaches in the drug development process, emphasizing that understanding the illness from the perspective of patients and caregivers is crucial for effective treatment design. The report details challenges faced by biopharmaceutical companies, including the difficulties in selecting appropriate clinical endpoints and engaging with patients. It highlights best practices for endpoint selection, such as employing a multidisciplinary approach and collaborating with regulators to validate endpoints. Additionally, the report discusses the complexities of site management in clinical trials, particularly for gene therapy involving pediatric populations. It also covers innovative trial designs, advocating for complex innovative designs (CIDs) that can efficiently address multiple questions and adapt based on interim data. Overall, the report aims to provide a comprehensive framework for improving the efficiency and effectiveness of rare disease treatment development.